CY1125058T1 - Δοσολογικο σχημα βαλβεναζινης για την αντιμετωπιση των κινητικων διαταραχων υπερκινητικοτητας - Google Patents

Δοσολογικο σχημα βαλβεναζινης για την αντιμετωπιση των κινητικων διαταραχων υπερκινητικοτητας

Info

Publication number
CY1125058T1
CY1125058T1 CY20221100104T CY221100104T CY1125058T1 CY 1125058 T1 CY1125058 T1 CY 1125058T1 CY 20221100104 T CY20221100104 T CY 20221100104T CY 221100104 T CY221100104 T CY 221100104T CY 1125058 T1 CY1125058 T1 CY 1125058T1
Authority
CY
Cyprus
Prior art keywords
movement disorders
valvenazine
dosage
treatment
hyperactivity
Prior art date
Application number
CY20221100104T
Other languages
English (en)
Inventor
Christopher F. O'BRIEN
Original Assignee
Neurocrine Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences, Inc. filed Critical Neurocrine Biosciences, Inc.
Publication of CY1125058T1 publication Critical patent/CY1125058T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Παρέχονται μέθοδοι για την αντιμετώπιση των κινητικών νόσων και διαταραχών υπερκινητικότητας, όπως η όψιμη δυσκινησία. Σε μια συγκεκριμένη υλοποίηση, ο ισχυρός VMAT2 αναστολέας (+)α-3-ισοβουτυλ-9,10-διμεθοξυ-1,3,4, 6,7,11b-εξαϋδρο-2Η-πυριδο[2,1-a]ισοκινολιν-2-όλη ((+)α-ΗΤΒΖ) χρησιμοποιείται στις μεθόδους που περιγράφονται εδώ για την αντιμετώπιση ενός ατόμου που τον έχει ανάγκη.
CY20221100104T 2014-05-06 2022-02-07 Δοσολογικο σχημα βαλβεναζινης για την αντιμετωπιση των κινητικων διαταραχων υπερκινητικοτητας CY1125058T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461989240P 2014-05-06 2014-05-06
PCT/US2015/029519 WO2015171802A1 (en) 2014-05-06 2015-05-06 Vmat2 inhibitors for the treatment of hyperkinetic movement disorders

Publications (1)

Publication Number Publication Date
CY1125058T1 true CY1125058T1 (el) 2023-06-09

Family

ID=53264772

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20221100104T CY1125058T1 (el) 2014-05-06 2022-02-07 Δοσολογικο σχημα βαλβεναζινης για την αντιμετωπιση των κινητικων διαταραχων υπερκινητικοτητας

Country Status (23)

Country Link
US (3) US20170071932A1 (el)
EP (2) EP3139925B1 (el)
JP (3) JP6635945B2 (el)
KR (4) KR20200133003A (el)
CN (3) CN112741836A (el)
AU (1) AU2015256012B2 (el)
CA (1) CA2947736C (el)
CY (1) CY1125058T1 (el)
DK (2) DK3936130T3 (el)
ES (1) ES2904526T3 (el)
FI (1) FI3936130T3 (el)
HR (1) HRP20220025T1 (el)
HU (1) HUE057839T2 (el)
IL (1) IL248745B (el)
LT (2) LT3139925T (el)
MX (1) MX2016014429A (el)
NZ (1) NZ725826A (el)
PL (1) PL3139925T3 (el)
PT (2) PT3139925T (el)
RS (2) RS62782B1 (el)
RU (1) RU2753740C2 (el)
SI (1) SI3139925T1 (el)
WO (1) WO2015171802A1 (el)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10065952B2 (en) 2015-10-30 2018-09-04 Neurocrine Biosciences, Inc. Valbenazine salts and polymorphs thereof
JP6869988B2 (ja) 2015-12-23 2021-05-12 ニューロクライン バイオサイエンシーズ，インコーポレイテッド （Ｓ）−（２Ｒ，３Ｒ，１１ｂＲ）−３−イソブチル−９，１０−ジメトキシ−２，３，４，６，７，１１ｂ−ヘキサヒドロ−１Ｈ−ピリド［２，１−ａ］イソキノリン−２−イル２−アミノ−３−メチルブタノエートジ（４−メチルベンゼンスルホネート）の調製のための合成方法
EP3473623B1 (en) * 2016-06-29 2020-07-15 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal forms of nbi-98854, preparation method therefor and use thereof
TW201827051A (zh) * 2016-12-02 2018-08-01 美商神經性分泌生物科學公司 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
US10703750B2 (en) 2017-01-10 2020-07-07 Sandoz Ag Crystalline valbenazine free base
CA3051829A1 (en) 2017-01-27 2018-08-02 Neurocrine Bioscienes, Inc. Methods for the administration of certain vmat2 inhibitors
US10954235B2 (en) 2017-02-27 2021-03-23 Sandoz Ag Crystalline forms of valbenazine salts
WO2018164996A1 (en) * 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
AU2018242134B2 (en) * 2017-04-01 2023-09-28 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine for use in the treatment a movement disorder
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705305D0 (en) * 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
US20190111035A1 (en) * 2017-04-01 2019-04-18 Adeptio Pharmaceuticals Limited Pharmaceutical compositions
WO2018178243A2 (en) * 2017-04-01 2018-10-04 Adeptio Pharmaceuticals Limited Pharmaceutical compositions
WO2018200605A1 (en) * 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
JP7250006B2 (ja) 2017-09-21 2023-03-31 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 高投与量バルベナジン製剤ならびにそれに関連する組成物、方法およびキット
US10993941B2 (en) 2017-10-10 2021-05-04 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
KR20200066661A (ko) 2017-10-10 2020-06-10 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
RU2020114598A (ru) * 2017-11-08 2021-12-09 Фореси Фармасьютикалс Ко., Лтд. Сложные эфиры дигидротетрабеназина
JP7212958B2 (ja) 2017-12-26 2023-01-26 ▲蘇▼州科睿思制▲葯▼有限公司 バルベナジントシル酸塩の結晶形及びその製造方法並びに用途
AU2019261403A1 (en) 2018-04-25 2020-11-12 Shinkei Therapeutics, Inc. Tetrabenazine transdermal delivery device
EP3806856A1 (en) 2018-06-14 2021-04-21 Neurocrine Biosciences, Inc. Vmat2 inhibitor compounds, compositions, and methods relating thereto
BR112021000019A2 (pt) 2018-08-15 2021-04-06 Neurocrine Biosciences Inc. Métodos para administração de certos inibidores de vmat2
WO2020070236A1 (en) 2018-10-04 2020-04-09 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
KR20220007105A (ko) * 2019-05-09 2022-01-18 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8039627B2 (en) * 2006-11-08 2011-10-18 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto
JP2010509336A (ja) * 2006-11-09 2010-03-25 ニューヨーク ユニバーシティ サンドイッチ材料の製造方法、ガラス／セラミック／ガラス複合構造物、ガラス／セラミック／ガラス、医科あるいは歯科補綴、およびガラス／ジルコニア／ガラスサンドイッチ材料
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
WO2011019956A2 (en) 2009-08-12 2011-02-17 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
AU2009303758B8 (en) 2008-09-18 2015-02-19 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
CN103003275A (zh) * 2010-06-01 2013-03-27 奥斯拜客斯制药有限公司 Vmat2的苯并喹啉酮抑制剂
AU2013318182C1 (en) 2012-09-18 2022-01-20 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
AU2015213778B2 (en) * 2014-02-07 2020-04-23 Neurocrine Biosciences, Inc. Pharmaceutical compositions comprising an antipsychotic drug and a VMAT2 inhibitor and uses thereof

Also Published As

Publication number Publication date
PT3936130T (pt) 2024-04-17
JP6635945B2 (ja) 2020-01-29
RU2016147523A (ru) 2018-06-08
US20200101063A1 (en) 2020-04-02
IL248745B (en) 2022-07-01
JP2021191799A (ja) 2021-12-16
NZ725826A (en) 2023-05-26
US20210196702A1 (en) 2021-07-01
KR20240011255A (ko) 2024-01-25
EP3139925B1 (en) 2021-12-01
KR20200133003A (ko) 2020-11-25
JP2017514850A (ja) 2017-06-08
MX2016014429A (es) 2017-04-06
KR20220140647A (ko) 2022-10-18
CA2947736C (en) 2023-04-18
CN106456629A (zh) 2017-02-22
RU2016147523A3 (el) 2018-12-28
HRP20220025T1 (hr) 2022-04-01
EP3936130B1 (en) 2024-02-14
LT3139925T (lt) 2022-01-25
DK3936130T3 (da) 2024-03-25
CN112741835A (zh) 2021-05-04
DK3139925T3 (da) 2021-12-20
WO2015171802A1 (en) 2015-11-12
CN112741836A (zh) 2021-05-04
FI3936130T3 (fi) 2024-04-23
PL3139925T3 (pl) 2022-03-21
PT3139925T (pt) 2022-01-26
RS65359B1 (sr) 2024-04-30
EP3139925A1 (en) 2017-03-15
US20170071932A1 (en) 2017-03-16
CA2947736A1 (en) 2015-11-12
AU2015256012A1 (en) 2016-11-24
AU2015256012B2 (en) 2020-07-23
EP3936130A1 (en) 2022-01-12
ES2904526T3 (es) 2022-04-05
HUE057839T2 (hu) 2022-06-28
SI3139925T1 (sl) 2022-04-29
IL248745A0 (en) 2017-01-31
LT3936130T (lt) 2024-04-25
RU2753740C2 (ru) 2021-08-23
JP2019218407A (ja) 2019-12-26
RS62782B1 (sr) 2022-01-31
KR20160147044A (ko) 2016-12-21

Similar Documents

Publication Publication Date Title
CY1125058T1 (el) Δοσολογικο σχημα βαλβεναζινης για την αντιμετωπιση των κινητικων διαταραχων υπερκινητικοτητας
CY1124368T1 (el) Μεθοδοι αυξησης της τονικης αναστολης και θεραπειας του συνδρομου angelman
CY1123354T1 (el) Συνθεσεις τοπικης εφαρμογης που περιλαμβανουν ενα κορτικοστεροειδες και ενα ρετινοειδες για τη θεραπεια της ψωριασης
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
EA201691582A1 (ru) Новые фармацевтические препараты
SV2017005419A (es) Triazolopirazinonas como inhibidores de pde1
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
EA201790273A1 (ru) Флагеллиновые композиции и их применение
DK3902547T3 (da) Csf1r-hæmmere til anvendelse i cancerbehandling
EA201791095A1 (ru) Способ лечения рака
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
EA201792157A1 (ru) Имидазопиразиноны в качестве ингибиторов pde1
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
DK3107899T3 (da) Mitokondriel aldehyddehydrogenase 2 (aldh2)-bindende polycykliske amider og anvendelse deraf til cancerbehandling
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
CY1117620T1 (el) Τριτοκαλινη για χρηση στην αντιμετωπιση της κυστικης ινωσης
AR112144A1 (es) Compuestos para el tratamiento del sarcoma
CL2016001937A1 (es) Compuestos de benzopirano funcionalizados y uso de los mismos
EA201692534A1 (ru) Способы лечения гипотонии
BR112017009000A2 (pt) apilimod para uso no tratamento de melanoma
MX2016015378A (es) Uso de eribulina en el tratamiento de cancer.
EA201790156A1 (ru) Азетидинилоксифенилпирролидиновые соединения
MX2020009709A (es) Composiciones farmaceuticas que comprenden acido dihomo-gamma-linolenico (dgla) y uso de las mismas.
EA201792123A1 (ru) Лечение боли